There were positive words from the CEO but the biotech giant has reported the loss after booking billions in restructuring and impairment charges, including a $US4.1bn writedown of its Vifor business.
There were positive words from the CEO but the biotech giant has reported the loss after booking billions in restructuring and impairment charges, including a $US4.1bn writedown of its Vifor business.
This content is for paid subscribers only.
Start your free trial nowor purchase a monthly or annual subscription to read.